Overview

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
Phase:
Phase 2
Details
Lead Sponsor:
Knopp Biosciences
Treatments:
Pramipexole